The following stories appear in full on today's Vidyya Medical News Service Web site.
Two new research studies in the November 30 issue of The New England Journal of Medicine reflect a rheumatoid arthritis (RA) research effort moving at a breathtaking pace, according to experts in the field. One study has shown that a combination of the drugs infliximab (RemicadeTM) and methotrexate significantly reduced the symptoms of RA and halted progression of joint damage over methotrexate treatment alone in a 54-week trial of 428 patients. The other reveals that etanercept (EnbrelTM), when compared to methotrexate alone, also arrested joint damage and more rapidly decreased symptoms in a 12-month trial of 632 patients.
For more information: New Drug Studies Show Promise For Reducing Joint Damage In Rheumatoid Arthritis
Remicade (infliximab) is a chimeric monoclonal antibody that binds to tumor necrosis factor alpha, which is believed to be central to the human body's reaction to inflammation. We have the prescribing information for you in today's issue.
For more information: Prescribing Information: Remicade
Enbrel (etanercept) is indicated for reducing signs and symptoms and delaying structural damage in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be used in combination with methotrexate (MTX) in patients who do not adequately respond to MTX alone. Get the full prescribing information in today's issue.
For more information: Prescribing Information: Enbrel
The pharmaceutical industry bid to block Vermont from offering cut-rate prescriptions to a broader range of people through Medicaid has taken the form of a law suit against the federal government.
For more information: Pharmaceutical Industry Files Suit Against Federal Government
Ascent Pediatrics, Inc. announced today that it has received approval from
the U.S. Food and Drug Administration to market Orapred(R) (prednisolone
sodium phosphate 20.2mg/5mL, equivalent to prednisolone 15mg/5mL) oral
solution as a treatment for children with asthma and other inflammatory
conditions. The company expects Orapred, which is available only by
prescription, to begin shipping to pharmacies in January.
For more information: FDA Approves Orapred®
Today's Vidyya articles are:
As always, we hope you enjoy the issue.